Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-09-30
2000-09-26
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, 530395, 4241851, 514 8, A61K 3800
Patent
active
061242608
ABSTRACT:
Peptides capable of interacting with smooth muscle cells are provided. Peptides are derived from Tenascin-C protein, particularly from the Fbg-L domain of Tenascin-C protein. Peptides of the present invention are useful in inhibiting smooth muscle cell migration. Methods of inhibiting smooth muscle cell adhesion and migration are also provided. Methods of the present invention may be used for treating intimal hyperplasia, restenosis, and atherosclerosis.
REFERENCES:
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5169930 (1992-12-01), Ruoslahti et al.
patent: 5246451 (1993-09-01), Trescony et al.
patent: 5512474 (1996-04-01), Clapper et al.
patent: 5622975 (1997-04-01), Singh et al.
patent: 5674848 (1997-10-01), Bhatnagar
patent: 5681931 (1997-10-01), Reid et al.
patent: 5684133 (1997-11-01), Schwab et al.
patent: 5710159 (1998-01-01), Voss et al.
LaFleur et al.;Aortic Smooth Muscle Cells Interact with Tenascin-C through its Fibrinogen-like Domain; FASEB Journal 12(4) pA479, Mar., 17, 1998.
Joshi et al.; Endothelial cells adhere to the RGD domain and the Fibrinogen-like terminal knob of tenascin; J. Cell Sci. 106 (pt 1); 389-400, 1993.
Chiquet et al.; Isolation of chick tenascin fvariants and fragments (A C-terminal heparin-binding fragment produced by cleavage of the extra domain from the largest subunit splicing variant); Eur. J. Biochem.; 199; 379-388, 1991.
Majesky et al.; Neointima Formation after Acute Vascular Injury; Texas Heart Inst. J. 21 (1) 78-85, 1994.
Wehrle-Haller et al.; J. of Cell Sci.; 106; 597-610, 1993.
David W. LaFleur et al., "Aortic Smooth Muscle Cells Interact with Tenascin-C through its Fibrinogen-like Domain," The Journal of Biological Chemistry, vol. 272, No. 52, pp. 32798-32803, 1997.
Gordon A.A. Ferns et al., "Inhibition of Neointimal Smooth Muscle Accumulation after Angioplasty by an Antibody to PDGF," Science, vol. 253, No. 5024, pp. 1129-1132, 1991.
Eric T. Choi, et al., "Inhibition of neointimal hyperplasia by blocking .alpha..sub.v .beta..sub.3 integrin with a small peptide antagonist GpenGRGDSPCA," Journal of Vascular Surgery, vol. 19, No. 1, pp. 125-134, 1994.
Daniel Kirchhofer et al., ".alpha..sub.2 .beta..sub.1 Integrins from Different Cell Types Show Different Binding Specificities," The Journal of Biological Chemistry, vol. 265, No. 2, pp. 615-618, 1990.
Aarno Hautanen et al., "Effects of Modifications of the RGD Sequence and Its Context on Recognition by the Fibronectin Receptor," The Journal of Biological Chemistry, vol. 264, No. 3, pp. 1437-1442, 1989.
Mario A. Bourdon et al., "Tenascin Mediates Cell Attachment through an RGD-dependent Receptor," The Journal of Cell Biology, vol. 108, pp. 1149-1155, Mar. 1989.
P. Sriramarao et al., "Endothelial Cell attachment and spreading on human tenascin is mediated by .alpha..sub.2 .beta..sub.1 and .alpha..sub.v .beta..sub.3 integrins," Journal of Cell Science, 105, pp. 1001-1012, 1993.
Enno Aufderheide et al., "Tenascin During Gut Development: Appearance in the Mesenchyme, Shift in Moledular Forms, and Dependence on Epithelial-Mesenchymal Interactions," The Journal of Cell Biology, vol. 107, No. 6, 2341-2349, 1988.
Paritosh Joshi et al., "Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin," Journal of Cell Science, 106, pp. 389-400, 1993.
Harold P. Erickson et al., "Tenascin: an Extracellular Matrix Protein Prominent in Specialized Embryonic Tissues and Tumors," Annu. Rev. Cell Biol., 1989 5:71-92.
Ikramuddin Aukhil et al., "Cell- and Heparin-binding Domains of the Hexabrachion Arm Identified by Tenascin Expression Proteins," Journal of Biological Chemistry, vol. 268, No. 4, pp. 2542-2553, 1993.
Shah Prediman K.
Sharifi Behrooz G.
Cedars-Sinai Medical Center
Chan Christina Y.
Nolan Patrick J.
LandOfFree
Inhibition of smooth muscle cell migration by Tenascin-C peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of smooth muscle cell migration by Tenascin-C peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of smooth muscle cell migration by Tenascin-C peptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100181